Autosomal dominant polycystic kidney disease (ADPKD), a hereditary renal disease caused by mutations in PKD1 (85%) or PKD2 (15%), is characterized by the development of gradually enlarging multiple renal cysts and progressive renal failure. Polycystin-1 (PC1), PKD1 gene product, is an integral membrane glycoprotein which regulates a number of different biological processes including cell proliferation, apoptosis, cell polarity, and tubulogenesis. PC1 is a target of various proteolytic cleavages and proteosomal degradations, but its role in intracellular signaling pathways remains poorly understood. Herein, we demonstrated that PC1 is a novel substrate for μ- and m-calpains, which are calcium-dependent cysteine proteases. Overexpression of PC1 altered both Janus-activated kinase 2 (JAK2) and extracellular signal-regulated kinase (ERK) signals, which were independently regulated by calpain-mediated PC1 degradation. They suggest that the PC1 function on JAK2 and ERK signaling pathways might be regulated by calpains in response to the changes in intracellular calcium concentration.

Download full-text PDF

Source

Publication Analysis

Top Keywords

jak2 erk
8
signaling pathways
8
pc1
6
calpain-mediated proteolysis
4
proteolysis polycystin-1
4
polycystin-1 c-terminus
4
c-terminus induces
4
induces jak2
4
erk signal
4
signal alterations
4

Similar Publications

Background: Precancerous lesions of gastric cancer (PLGC) represent critical stages in gastric cancer progression, with a high risk of malignancy. Current treatments, such as Helicobacter pylori eradication, show limited efficacy in reversing precancerous molecular changes. Zuojin Pill (ZJP), a traditional Chinese medicine, has demonstrated potential for treating digestive disorders and may offer a promising approach for PLGC intervention.

View Article and Find Full Text PDF

GHRH and the prostate.

Rev Endocr Metab Disord

November 2024

Departamento de Biología de Sistemas. Unidad de Bioquímica y Biología Molecular (Research group "Cánceres de origen epitelial"), Universidad de Alcalá, Campus Científico-Tecnológico, 28871, Alcalá de Henares, Madrid, Spain.

Article Synopsis
  • In the late 1960s and early 1970s, researchers isolated and studied hypothalamic regulatory hormones, discovering both normal and tumor tissues can produce growth hormone-releasing hormone (GHRH).
  • GHRH receptors, particularly the pituitary-type (pGHRH-R), are predominantly found in the anterior pituitary but also in other body cells and various cancers, including prostate cancer, with splice variants detected in these tissues.
  • GHRH activates multiple signaling pathways that promote cell survival and proliferation, making GHRH receptors potential drug targets, especially in prostate conditions, with recent antagonists showing enhanced anticancer and anti-inflammatory effects.
View Article and Find Full Text PDF

The increasing global cancer burden necessitates the development of new treatment options. Herbal medicine offers a viable alternative to conventional cancer treatments. Numerous studies have shown that 3-dimensional (3D) cell culture more accurately represents tumor characteristics in vivo.

View Article and Find Full Text PDF

Targeting KRAS-mutant pancreatic cancer through simultaneous inhibition of KRAS, MEK, and JAK2.

Mol Oncol

October 2024

Division of Gastroenterological, Hepato-Biliary-Pancreatic, Transplantation and Pediatric Surgery, Department of Surgery, Shinshu University School of Medicine, Matsumoto, Japan.

Article Synopsis
  • The KRAS oncogene was previously deemed "undruggable," but the KRAS inhibitors sotorasib and MRTX1133 have shown promising results for lung cancers, while MRTX1133 is less effective for pancreatic cancer when used alone.
  • Researchers discovered that these KRAS inhibitors increase certain cellular signals (STAT3 and ERK), which could lead to cancer resistance.
  • Combining KRAS inhibitors with MEK and JAK2 inhibitors (like trametinib and fedratinib) could enhance treatment outcomes and tackle resistance in KRAS-mutant pancreatic cancer effectively.
View Article and Find Full Text PDF

Long noncoding RNA MEG3: an active player in fibrosis.

Pharmacol Rep

February 2025

Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Xi'an Jiaotong University Health Science Center, 76 Yanta West Road, Xi'an, Shaanxi, 710061, China.

Fibrosis, characterized by excess accumulation of extracellular matrix components, disrupts normal tissue structure and causes organ dysfunction. Long noncoding RNAs (lncRNAs) are a subset of RNAs longer than 200 nucleotides that are not converted into proteins. The increasing research indicated that lncRNA maternally expressed gene 3 (MEG3) was dysregulated in the pathologic process of fibrosis in several tissues.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!